Why the study?
Inflammation is closely linked to tumor development and prognosis, prompting evaluation of the prognostic value of preoperative inflammatory indexes in pediatric hepatoblastoma patients receiving neoadjuvant chemotherapy.
Does the systemic inflammation response index (SIRI) predict overall survival in pediatric hepatoblastoma patients receiving neoadjuvant chemotherapy?
Does the systemic inflammation response index (SIRI) predict overall survival in pediatric hepatoblastoma patients receiving neoadjuvant chemotherapy?
The systemic inflammation response index (SIRI) is an independent prognostic factor for overall survival in pediatric hepatoblastoma patients receiving neoadjuvant chemotherapy.
No takes yet. Share an insight, caveat, or question.
High preoperative SIRI independently predicts worse OS in pediatric hepatoblastoma after neoadjuvant chemotherapy; leaves open its routine prognostic use pending prospective validation.
Chen et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: